Abstract 1288P
Background
Neoadjuvant chemotherapy (CT) has limited benefit over surgery alone for resectable non-small cell lung cancer (NSCLC). Recent trials have shown promising results for combining immune checkpoint inhibitors with platinum-doublet chemotherapy (ICI plus CT).
Methods
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) that compared neoadjuvant ICI plus CT versus CT alone in patients with resectable NSCLC. We searched PubMed, Scopus, and Cochrane Library databases, as well as the ASCO, ESMO, and AACR websites. We used a fixed effects model for analysis and assessed heterogeneity with I2 statistics.
Results
We included six RCTs with 2,471 patients, of whom 75% were male, 47% had non-squamous, and 53% had squamous cell carcinoma (SCC). The median age was 63.3 years (ranged from 29 to 88). After neoadjuvant therapy, 84% of patients in the ICI plus CT group underwent surgery compared to 81% in the CT group (p=0.16); R0 resection was reported in 78% versus 67% of patients (p<0.01), respectively. We found a significantly higher pathologic complete response (risk ratio [RR] 5.81 [95%CI 4.26-7.92]) and major pathologic response (RR 3.57 [3.09-4.55]) in patients who received ICI plus CT than those in the CT group. Treatment with ICI plus CT provided a greater benefit of event-free survival (EFS) (HR 0.59 95%CI 0.51-0.67 p<0.00001) and overall survival (HR 0.66 95%CI 0.53-0.82 p=0.0002)compared to CT alone. ICI plus CT improved EFS regardless of PD-L1 expression, type of platinum CT, or histology. Patients with PD-L1 ≥1% achieved considerably better EFS than those with PD-L1 <1% (HR 0.40 vs 0.76, p<0.0001). Subgroup analysis showed EFS benefit for all stages (IB and II, IIIA, and IIIB). Treatment-related adverse events grades 3 or 4 were seen in 36% of patients in the intervention arm and 32% of the control arm (p=0.05).
Conclusions
Neoadjuvant therapy with anti-PD-1/PD-L1 plus CT provided significantly higher pathologic response, EFS, and OS compared to CT alone for resectable stage II-III NSCLC patients. More mature data from the trials are awaited to confirm these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1276P - Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Presenter: Kiyotaka Yoh
Session: Poster session 04
1277P - HRD status of patients with early stage non-small cell lung cancer
Presenter: Apostolos Klinakis
Session: Poster session 04
1278P - ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain
Presenter: Ernest Nadal
Session: Poster session 04
1279P - Prevalence of EGFR mutations (EGFRm) in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR LATAM
Presenter: Edgar Amorin
Session: Poster session 04
1280P - Comprehensive characterization of human lung squamous cell carcinoma identifies high TFRC expression as a mark of poorly immunogenic tumours
Presenter: María Gutiérrez Pérez
Session: Poster session 04
1281P - Effect of Fra-2 expression on tumour immunogenicity and prognosis in KRAS-mutant lung adenocarcinoma
Presenter: Alvaro Ucero
Session: Poster session 04
1282P - Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Presenter: Yoshitaka Zenke
Session: Poster session 04
1283P - Predicting PD-L1 expression using [18F]FDG PET/CT in early stage non-small cell lung cancer (NSCLC)
Presenter: Daniel Hughes
Session: Poster session 04
1284P - Lung cancer among patients with chronic obstructive pulmonary disease: A Danish 10-year observational study of the overlapping population
Presenter: Margrethe Henriksen
Session: Poster session 04
1285P - Lung cancer in never smokers (LCINS): Clinicopathological characteristics and treatment outcomes from a university cancer centre in London
Presenter: Charalampos Gousis
Session: Poster session 04